Deutsche Bank analysts expect to see substantial growth opportunities in China’s monoclonal antibodies (mAbs) market in the coming five years. These are therapies used in the treatment of serious conditions such as cancer, rheumatoid arthritis, Crohn’s diseases, and osteoporosis.Photo: AFP
Latest type of biological therapy, monoclonal antibodies, tipped as having huge potential in China
Deutsche Bank analysts predict mAbs market to see 24pc compound annual growth from 2017 to 2022 after the first major approval in 2018
Topic |
Broker's View
Deutsche Bank analysts expect to see substantial growth opportunities in China’s monoclonal antibodies (mAbs) market in the coming five years. These are therapies used in the treatment of serious conditions such as cancer, rheumatoid arthritis, Crohn’s diseases, and osteoporosis.Photo: AFP